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o r i g i n a l a r t i c l e
Attributable Costs of Enterococcal Bloodstream Infections
in a Nonsurgical Hospital Cohort
Anne M. Butler, MS; Margaret A. Olsen, PhD, MPH; Liana R. Merz, PhD, MPH; Rebecca M. Guth, MPH;
Keith F. Woeltje, MD, PhD; Bernard C. Camins, MD, MSCR; Victoria J. Fraser, MD
background. Vancomycin-resistant Enterococcus (VRE) bloodstream infections (BSIs) are associated with increased morbidity and
mortality.
objective. To determine the hospital costs and length of stay attributable to VRE BSI and vancomycin-sensitive Enterococcus (VSE)
BSI and the independent effect of vancomycin resistance on hospital costs.
methods. A retrospective cohort study was conducted of 21,154 nonsurgical patients admitted to an academic medical center during
the period from 2002 through 2003. Using administrative data, attributable hospital costs (adjusted for inflation to 2007 US dollars) and
length of stay were estimated with multivariate generalized least-squares (GLS) models and propensity score–matched pairs.
results. The cohort included 94 patients with VRE BSI and 182 patients with VSE BSI. After adjustment for demographics, comorbidities,
procedures, nonenterococcal BSI, and early mortality, the costs attributable to VRE BSI were $4,479 (95% confidence interval [CI], $3,500–
$5,732) in the standard GLS model and $4,036 (95% CI, $3,170–$5,140) in the propensity score–weighted GLS model, and the costs
attributable to VSE BSI were $2,250 (95% CI, $1,758–$2,880) in the standard GLS model and $2,023 (95% CI, $1,588–$2,575) in the
propensity score–weighted GLS model. The median values of the difference in costs between matched pairs were $9,949 (95% CI, $1,579–
$24,693) for VRE BSI and $5,282 (95% CI, $2,042–$8,043) for VSE BSI. The costs attributable to vancomycin resistance were $1,713 (95%
CI, $1,338–$2,192) in the standard GLS model and $1,546 (95% CI, $1,214–$1,968) in the propensity score–weighted GLS model. Depending
on the statistical method used, attributable length of stay estimates ranged from 2.2 to 3.5 days for patients with VRE BSI and from 1.1
to 2.2 days for patients with VSE BSI.
conclusions. VRE BSI and VSE BSI were independently associated with increased hospital costs and increased length of stay. Vancomycin
resistance was associated with increased costs.
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Bloodstream infections (BSIs) due to vancomycin-resistant
Enterococcus (VRE) are associated with increased morbidity,
mortality, and hospital costs.1-4 Rates of vancomycin resis-
tance among enterococcal isolates, which are among the most
common pathogens associated with nosocomial BSI,5 have
increased substantially during the past decade.6 In 2003, the
pooled mean proportion of enterococcal infections resistant
to vancomycin among patients in intensive care units was
28.5%, as reported to the Centers for Disease Control and
Prevention’s National Nosocomial Infections Surveillance
system.6 Although the incidence of infections due to VRE is
higher in intensive care unit patients, VRE infections are also
common among patients treated in noncritical care units.
Since infection control measures to prevent transmission of
VRE BSI are effective but resource intensive,7 accurate esti-
mates of the attributable cost of enterococcal BSI infections
are necessary to assess the cost effectiveness of prevention
strategies.
Despite the increasing prevalence of VRE in US hospitals,
the financial burden of infection due to enterococcal path-
ogens has not been adequately explored.8 We are aware of
only 2 published studies that estimate the hospital costs as-
sociated with VRE BSI.1,4 However, neither study adequately
controlled for underlying severity of illness or hospital pro-
cedures that may affect the cost of care, which may have
resulted in biased cost estimates. In addition, there are limited
cost data regarding the independent impact of acquiring a
vancomycin resistance phenotype of a particular pathogen.
Estimation of the independent effects of a resistance trait or
phenotype (eg, vancomycin resistance) necessitates the use of
a control group of patients infected with a sensitive organism
(eg, vancomycin sensitive) rather than a control group of
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uninfected patients.8,9 Prior studies that compared infections
due to vancomycin-sensitive pathogens with infections due
to vancomycin-resistant pathogens were limited by small
sample size and/or inadequate adjustment for potential con-
founding by comorbidities.9,10 The purpose of our study was
to estimate the hospital costs and length of stay attributable
to vancomycin-sensitive Enterococcus (VSE) BSI and VRE BSI
in a nonsurgical hospital cohort by using administrative data
and 3 reproducible analytical methods. We also sought to
determine the independent effect of vancomycin resistance
on hospital costs.
methods
Study Design
Nonsurgical patients admitted to Barnes-Jewish Hospital dur-
ing the period from January 2002 through December 2003
who were hospitalized for more than 48 hours were included
in the study. Surgical patients were excluded from the analysis
because the distribution of costs was different for patients
who incurred operating room costs. Data on demographics,
inpatient mortality, microbiology results, and International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) diagnosis and procedure codes were obtained
from the hospital Medical Informatics database. ICD-9-CM
diagnosis codes were collected for all patients who had been
admitted during the past 2 years. ICD-9-CM procedure codes
were collected only for the most recent hospitalization of each
patient. Comorbidity and procedure variables were created
from ICD-9-CM codes with guidance from the Healthcare
Cost and Utilization Project Clinical Classifications Software
(Agency for Healthcare Research and Quality). The presence
of a central venous catheter was defined according to ICD-
9-CM codes assigned during the 6-month period before en-
terococcal BSI infection for case patients or during the 6-
month period before hospital discharge for uninfected control
patients, with the assumption that central venous catheters
inserted after diagnosis of infection were used for therapeutic
purposes and that these costs needed to be captured in the
costs of the infection.
Cases of enterococcal BSI were identified on the basis of
positive blood culture results during hospitalization. Each
patient’s first episode of enterococcal BSI was analyzed. In
the event of a polymicrobial BSI with both VSE and VRE
organisms, the patient was classified as having a VRE BSI.
Patients who had never had a BSI served as the control group.
For control patients who were hospitalized more than once
during the study period, 1 hospitalization per patient was
randomly selected for analysis.
Hospital cost data (from the hospital payer perspective)
were obtained from the Barnes-Jewish Hospital cost account-
ing database (Trendstar; McKesson). The departmental cost
for each charge code assigned during hospitalization was cal-
culated as the proportion of total departmental charges ac-
counted for by the charge code multiplied by the depart-
ment’s actual cost components. Departmental costs were
summed to calculate total hospital costs for each hospitali-
zation and were adjusted for inflation to 2007 US dollars
according to the medical care component of the Consumer
Price Index.11
Statistical Analyses
Patient characteristics were compared by using the Student
t test, the x2 test, or the Fisher exact test. Crude costs and
hospital length of stay were compared by using the Mann-
Whitney U test. Three methods (ie, standard regression ad-
justment, propensity score–weighted regression adjustment,
and propensity score–matched pairs) were used to estimate
total hospital costs and hospital length of stay associated with
VRE BSI and VSE BSI, in order to control for the variation
of many factors significantly associated with expenditures.
Standard Generalized Least-Squares Model
A generalized least-squares (GLS) regression model was fit
with total cost as the dependent variable; total cost was natural
log–transformed because of the highly skewed distribution of
costs. The multivariate GLS model was developed by using
backward stepwise regression, including all variables associ-
ated with the natural logarithm of cost in the bivariate analysis
( ) or biologic plausibility. Variables that applied toP X .05
fewer than 10 patients were excluded from the analysis. A
“feasible GLS estimator” was used to weight the observations
to account for heteroskedasticity.12 Since the GLS model used
the natural logarithm of costs as the dependent variable, an
intermediate regression was performed to predict costs. Each
coefficient obtained in the GLS model represented the mean
difference in the natural logarithm of costs between individ-
uals with that variable and individuals without that variable,
assuming all other predictors of costs remained constant. The
attributable costs were calculated by solving the regression
equation separately for each variable of interest (ie, VSE BSI,
VRE BSI, and vancomycin resistance). Specifically, each co-
efficient was multiplied by the proportion of patients with
that particular covariate and added to the constant, with the
exception of nonenterococcal BSI. This exclusion allowed the
adjusted costs of the uninfected control group to represent
the “average” patient without nonenterococcal BSI. All in-
dependent variables were checked for collinearity. Models
were checked for functional form misspecification by means
of the Ramsey regression specification error test and for het-
eroskedasticity by means of the Breusch-Pagan test.12 To assess
the impact of vancomycin resistance, a second standard GLS
model was fit with enterococcal BSI and vancomycin resis-
tance as the primary independent variables. Attributable hos-
pital length of stay was calculated by using this final model
with the natural logarithm of length of stay as the dependent
variable.
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Propensity Score–Weighted GLS Model
A GLS regression model adjusted for propensity score inverse
weighting was also used to estimate attributable costs.13,14 The
predicted probabilities for development of enterococcal BSI
(ie, VSE BSI and/or VRE BSI) were obtained from a multi-
variate logistic regression model that included all variables
with P less than .20 in bivariate analysis. Each case patient
was weighted by the inverse of the propensity score, and each
control patient was weighted by the inverse of 1 minus the
propensity score.13,14 The final regression model included the
primary independent variables (ie, enterococcal BSI and van-
comycin resistance), as well as all covariates that were un-
balanced in at least 1 quintile of the propensity score. A
second propensity score–weighted GLS model was also fit
with enterococcal BSI and vancomycin resistance as the pri-
mary independent variables. Attributable hospital length of
stay was calculated by using this final model with the natural
logarithm of length of stay as the dependent variable.
Propensity Score–Matched Pairs
Propensity score–matched pairs analyses were used to esti-
mate the attributable costs and attributable length of stay of
VSE BSI and VRE BSI. The predicted probabilities for de-
velopment of VSE BSI or VRE BSI were obtained from sep-
arate multivariate logistic regression models that included all
biologically plausible variables associated with VSE BSI in the
bivariate analysis ( ). Case patients with BSI due toP ! .20
VSE were matched 1 : 1 to uninfected control patients on the
basis of their propensity to develop VSE BSI, and case patients
with BSI due to VRE were matched 1 : 1 to uninfected con-
trol patients on the basis of their propensity to develop VRE
BSI, using the nearest neighbor method within calipers of
0.25 standard deviations.15,16 Case patients who could not be
matched with a suitable control patient were excluded from
the analyses. Matched and unmatched case patients were com-
pared by means of the x2 test or the Fisher exact test, with
Bonferroni correction. Because of highly skewed cost data, at-
tributable costs and attributable length of stay were presented
as the median value of the difference in costs and length of
stay, respectively, between matched pairs and were compared
using the Wilcoxon signed rank test. Confidence intervals were
calculated on the basis of the binomial distribution.
Statistical analyses were performed with SPSS, version 15.0
(SPSS), and Stata, version 9.2 (StataCorp). Approval for this
study was obtained from the Washington University Human
Research Protection Office.
results
During the 2-year study period, 21,154 nonsurgical patients
were admitted to Barnes-Jewish Hospital and hospitalized for
more than 48 hours (Table 1). Of the 276 patients (1%)
identified with an enterococcal BSI, 94 (34%) had BSI due
to VRE and 182 (66%) had BSI due to VSE. Enterococcal
BSI occurred significantly more often in patients with ICD-
9-CM comorbidity codes for congestive heart failure, acute
renal failure, Clostridium difficile infection, or urinary tract
infection and in patients with ICD-9-CM procedure codes
for bone marrow transplant, mechanical ventilation, hemo-
dialysis, cancer chemotherapy, or placement of a central ve-
nous catheter (excluding catheters placed to administer an-
tibiotics for treatment of enterococcal BSI). Patients with an
enterococcal BSI were more likely than patients without an
enterococcal BSI to have been in an intensive care unit (41
[44%] of 94 patients with VRE BSI and 62 [34%] of 182
patients with VSE BSI vs 3,330 [16%] of 20,878 patients
without enterococcal BSI; for both) and were moreP ! .001
likely to die in the hospital (30 [32%] of 94 patients with
VRE BSI and 31 [17%] of 182 patients with VSE BSI vs 845
[4%] of 20,878 patients without enterococcal BSI; P ! .001
for both).
Crude costs and hospital length of stay are presented in
Table 2. Patients with BSI due to VRE incurred significantly
higher total crude median costs, compared with patients with
BSI due to VSE ( ) and compared with patients with-P ! .001
out BSI ( ). Median departmental costs were signifi-P ! .001
cantly higher for patients with VRE BSI, as well as for patients
with VSE BSI, compared with patients without BSI (P !
for all). The crude median costs attributable to VRE BSI.001
were $33,914, and those attributable to VSE BSI were $12,703.
The median hospital length of stay was significantly longer
for patients with VRE BSI (14.6 days) and patients with VSE
BSI (10.0 days), compared with patients without enterococcal
BSI (4.0 days; for both). The crude increases in lengthP ! .001
of hospital stay were 10.6 days for patients with VRE BSI and
6.0 days for patients with VSE BSI ( for both).P ! .001
Standard GLS Model and Propensity Score–Weighted GLS
Model
Both VRE BSI and VSE BSI were independent predictors of
hospital costs ( ) in the standard GLS model and theP ! .001
propensity score–weighted GLS model after controlling for
significant cost predictors, including demographics, comor-
bidities, procedures, nonenterococcal BSI, and early mortality.
After these adjustments, nonenterococcal BSI was also as-
sociated with significantly increased costs ( ). TheP ! .001
standard GLS model and the propensity score–weighted GLS
model had adjusted coefficients of determination (R2) of .42
and .38, respectively, indicating that approximately 40% of
the variation in costs was explained by the models.
The attributable cost estimates from the GLS models are
presented in Table 3. In the standard GLS model, the adjusted
cost of BSI due to VRE was $4,479 (95% confidence interval
[CI], $3,500–$5,732), and the adjusted cost of BSI due to
VSE was $2,250 (95% CI, $1,758–$2,880). In the propensity
score–weighted GLS model, the adjusted cost of VRE BSI was
$4,036 (95% CI, $3,170–$5,140), and the adjusted cost of
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table 1. Characteristics of Patients with and without Enterococcal Bloodstream Infection (BSI) ( )Np 21,154
Characteristic
Case patients
with VRE BSI
(n p 94)
Case patients
with VSE BSI
(n p 182)
Control patients
with no VRE
or VSE BSI
(n p 20,878)
P
VRE BSI vs
VSE BSI
VRE BSI vs
no VRE or
VSE BSI
VSE BSI vs
no VRE or
VSE BSI
Age, median (range), years 58.3 (20.9–88.0) 65.4 (18.1–98.2) 60.1 (14.0–106.2) .005 !.001 .004
Female sex 48 (51.1) 102 (56.0) 11,154 (53.4) .431 .647 .481
African American 42 (44.7) 84 (46.2) 7,485 (35.9) .816 .075 .004
Comorbidities
Acute cerebrovascular disease 4 (4.3) 9 (4.9) 1,037 (5.0) 1.999 1.999 .989
Acute myocardial infarction 10 (10.6) 9 (4.9) 1,308 (6.3) .077 .081 .464
Atrial fibrillation 15 (16.0) 39 (21.4) 2,603 (12.5) .278 .307 !.001
Congestive heart failure, nonhypertensive 28 (29.8) 66 (36.3) 4,354 (20.9) .282 .034 !.001
Pulmonary embolism and pulmonary hypertension 8 (8.5) 25 (13.7) 1,128 (5.4) .205 .184 !.001
Chronic obstructive pulmonary disease 20 (21.3) 34 (18.7) 3,012 (14.4) .607 .060 .104
Pneumonia 20 (21.3) 20 (11.0) 1,692 (8.1) .021 !.001 .156
Asthma 6 (6.4) 13 (7.1) 1,390 (6.7) .813 .915 .794
Diabetes mellitus
Without complications 19 (20.2) 51 (28.0) 4,316 (20.7) .158 .913 .015
With complications 12 (12.8) 29 (15.9) 1,564 (7.5) .483 .053 !.001
Acute renal failure 37 (39.4) 46 (25.3) 2,091 (10.0) .016 !.001 !.001
Hepatic disease 14 (14.9) 16 (8.8) 1,547 (7.4) .123 .006 .479
Diarrhea due to Clostridium difficile 19 (20.2) 24 (13.2) 433 (2.1) .127 !.001 !.001
Urinary tract infection 29 (30.9) 57 (31.3) 3,383 (16.2) .937 !.001 !.001
Nonenterococcal BSIa 54 (57.4) 76 (41.8) 728 (3.5) .013 !.001 !.001
Procedures
Placement of central venous catheterb 61 (64.9) 89 (48.9) 2,677 (12.8) .011 !.001 !.001
Hemodialysis 15 (16.0) 12 (6.6) 588 (2.8) .013 !.001 .002
Mechanical ventilation 27 (28.7) 36 (19.8) 1,145 (5.5) .062 !.001 !.001
Abdominal paracentesis 10 (10.6) 6 (3.3) 439 (2.1) .013 !.001 .289
Receipt of bone marrow transplant 9 (9.6) 14 (7.7) 213 (1.0) .592 !.001 !.001
Receipt of cancer chemotherapy 15 (16.0) 20 (11.0) 599 (2.9) .240 !.001 !.001
note. Data are no. (%) of patients unless otherwise indicated. NS, nonsignificant; VRE, vancomycin-resistant Enterococcus; VSE, vancomycin-sensitive
Enterococcus.
a Defined as at least 1 blood culture result positive for a nonenterococcal pathogen or at least 2 blood culture results positive for potential skin contaminants
(eg, coagulase-negative staphylococci or Micrococcus sp).
b Inserted before the onset of enterococcal BSI for case patients.
VSE BSI was $2,023 (95% CI, $1,588–$2,575). In the al-
ternative models with enterococcal BSI and vancomycin re-
sistance as the primary independent variables, vancomycin
resistance was an independent predictor of hospital costs
( ). The attributable cost of vancomycin resistancePp .001
ranged from $1,713 (95% CI, $1,338–$2,192) with the stan-
dard GLS model to $1,546 (95% CI, $1,214–$1,968) with the
propensity score–weighted GLS model.
Table 3 also presents the attributable length of stay esti-
mates. In the standard GLS model, the attributable length of
stay due to VRE BSI was 2.3 days (95% CI, 1.8–2.8 days),
and the attributable length of stay due to VSE BSI was 1.2
days (95% CI, 0.9–1.5 days). In the propensity score–
weighted GLS model, the length of stay attributable to VRE
BSI was 2.2 days (95% CI, 1.7–2.7 days), and the length of
stay attributable to VSE BSI was 1.1 days (95% CI, 0.9–1.4
days). The standard GLS model and the propensity score–
weighted GLS model had adjusted coefficients of determi-
nation (R2) of 0.35 and 0.33, respectively, indicating that ap-
proximately 34% of the variation in hospital length of stay
was explained by the models.
Propensity Score–Matched Pairs
On the basis of the predicted probabilities of developing VRE
BSI or VSE BSI, 88 (94%) of 94 case patients with VRE BSI
and 179 (98%) of 182 case patients with VSE BSI were suc-
cessfully matched with uninfected control patients. Six case
patients with VRE BSI and 3 case patients with VSE BSI were
excluded from the analyses as a result of the absence of a
suitable nearest neighbor control patient. All covariates were
balanced between matched and unmatched case patients, ad-
justing for multiple comparisons. While there were no sig-
nificant differences in median costs between unmatched and
matched VSE case patients ($23,013 vs $20,076; ),Pp .417
median costs were significantly higher for the 6 unmatched
VRE case patients, compared with the 88 matched VRE case
patients ($182,763 vs $40,140; ).Pp .029
The difference in total costs between the matched VRE BSI
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table 2. Crude Median Hospital Cost and Length of Stay of Patients with and without Enterococcal
Bloodstream Infection (BSI)
Outcomes
Case patients
with VRE BSIa
(n p 94)
Case patients
with VSE BSIa
(n p 182)
Control patients
without BSIb
(n p 20,150)
Hospital length of stay, days 14.6 (7.3–28.3) 10.0 (4.9–17.6) 4.0 (2.9–6.2)
Departmental costs, 2007 US$
Room and board 20,213 (7,209–45,610) 10,127 (5,829–21,212) 3,976 (2,793–6,456)
Pharmacy 7,430 (3,095–20,241) 3,205 (1,397–6,925) 669 (339–1,339)
Laboratory 4,143 (1,804–10,569) 1,989 (1,172–4,716) 628 (375–1,103)
Radiology 1,942 (940–4,591) 1,222 (501–2,053) 554 (125–1,197)
Respiratory therapy 412 (0–1,510) 130 (0–719) 0 (0–152)
Physical therapy 172 (0–448) 114 (0–370) 0 (0–175)
Otherc 3,710 (1,907–7,061) 2,193 (1,380–3,636) 1,140 (656–2,245)
Total costs 42,106 (16,310–93,870) 20,895 (11,263–41,879) 8,192 (5,615–13,495)
note. All data are median values (interquartile range). VRE, vancomycin-resistant Enterococcus; VSE, vancomycin-
sensitive Enterococcus.
a for all comparisons with uninfected control group. for all comparisons of patients with VRE BSI withP ! .001 P ! .001
patients with VSE BSI, with the exceptions of respiratory costs ( ) and physical therapy costs ( ).Pp .015 Pp .205
b Defined as patients without enterococcal or nonenterococcal BSI.
c Defined as costs not allocated to room and board, pharmacy, laboratory, radiology, respiratory therapy, or physical
therapy departments.
case and control pairs was $9,949 (median), and the difference
in total costs between the matched VSE BSI case and control
pairs was $5,282 (median) (Table 3). The median values for
the difference in hospital length of stay for the matched pairs
were equal to 3.5 days for VRE BSI and 2.2 days for VSE BSI
( for both, using the Wilcoxon signed rank test).P ! .001
discussion
In this retrospective cohort of nonsurgical patients admitted
to a university-affiliated tertiary care hospital, we used ad-
ministrative data and readily reproducible methods to esti-
mate the costs attributable to enterococcal BSI and vanco-
mycin resistance. VRE BSI and VSE BSI were independently
associated with significantly increased hospital costs after ad-
justment for other cost predictors, including demographics,
comorbidities, procedures, nonenterococcal BSI, and early
mortality. In addition, we determined that vancomycin re-
sistance was independently associated with increased hospi-
tal expenditures. To our knowledge, this is the first study
to report that enterococcal BSI due to vancomycin-resistant
strains is independently associated with increased hospital
costs. In this era of increasing antimicrobial resistance, ac-
curate estimates of the financial burden associated with nos-
ocomial infections are important for evaluating the cost-ef-
fectiveness of prevention strategies.
Since patients with infection often have more severe un-
derlying diseases that are independently predictive of adverse
outcomes and increased costs, adjustment for underlying se-
verity of illness is essential for accurate cost estimation.8 In
our cohort, patients who developed enterococcal BSI were
much more likely than uninfected control patients to have
risk factors for developing a BSI, including diabetes mellitus,
congestive heart failure, cancer, and receipt of a bone marrow
transplant. Given that the large differences in observed co-
variates between patients with enterococcal BSI and patients
without enterococcal BSI could lead to biased estimates of
costs, we used 3 different analytical methods to adjust for the
variation of factors significantly associated with expenditures.
In this cohort, we calculated the crude median attributable
cost of VRE BSI to be $33,914. After adjustment for an ex-
tensive number of comorbidities and procedures that were
associated with hospital expenditures, the VRE BSI cost es-
timates were $4,479 in the standard GLS model and $4,036
in the propensity score–weighted GLS model. The cost es-
timate generated by the propensity score–matched pairs
method ($9,949) was more than twice as large as the GLS
model estimates, despite the exclusion of 6 case patients with
VRE BSI (6%) who had significantly higher median costs
than the 88 case patients with VRE BSI (94%) who were
included in the analysis. The disparity between the cost es-
timates generated by the GLS models and those generated by
the matched pairs may be due, in part, to different control
groups. The control group in the GLS models was composed
of “average” uninfected patients, because we used the mean
of all covariates (except nonenterococcal BSI) to calculate
attributable costs; however, the control group in the matched-
pairs analysis was limited to a more severely ill subset of
patients. Since patients with enterococcal BSI tend to be sicker
than the average patient, the results of the matched-pairs
analysis suggest that VRE BSI in sicker patients is associated
with approximately $10,000 in additional hospital costs. The
matched-pairs design is an effective method for eliminating
bias, but the reduction in sample size reduces the precision
of cost estimates. This provides justification for the propensity
attributable costs of enterococcal bsi 33
table 3. Attributable Costs and Length of Stay Associated with Vancomycin-Resistant Enterococcus (VRE) and Vancomycin-Sensitive
Enterococcus (VSE) Bloodstream Infections (BSIs)
Statistical method
Costs,
US$ (95% CI)
Length of stay,
days (95% CI)
VRE BSI VSE BSI VRE BSI VSE BSI
GLS regression model, mean value $4,479 (3,500–5,732) $2,250 (1,758–2,880) 2.3 (1.8–2.8) 1.2 (0.9–1.5)
GLS regression model with IPW, mean valuea $4,036 (3,170–5,140) $2,023 (1,588–2,575) 2.2 (1.7–2.7) 1.1 (0.9–1.4)
Matched pairsa,b $9,949 (1,579–24,693) $5,282 (2,042–8,043) 3.5 (2.1–7.3) 2.2 (1.0–3.5)
note. CI, confidence interval; GLS, generalized least squares; IPW, inverse probability weighting.
a The variables in the logistic regression model used to create the propensity score for development of VSE BSI or VRE BSI include demographic variables
(age [by 5-year intervals], nonwhite race, and sex), medical conditions (pneumonia, aspiration pneumonitis, chronic obstructive pulmonary disease and
bronchiectasis, nonhypertensive congestive heart failure, pulmonary heart disease, coronary atherosclerosis, cardiac dysrhythmias not including atrial fibril-
lation, hypertension with complications and secondary hypertension, heart valve disorders, cardiac arrest and ventricular fibrillation, atrial fibrillation, atrial
flutter, conduction disorders, peri-, endo-, and myocarditis, hyperlipidemia, diabetes mellitus without complications, diabetes mellitus with complications,
chronic renal failure, acute renal failure, solid tumor malignancy, leukemia, non-Hodgkin’s lymphoma, multiple myeloma, human immunodeficiency virus
infection, Clostridium difficile diarrhea, urinary tract infection, infective arthritis and osteomyelitis, rheumatoid arthritis, agranulocytosis [neutropenia],
peritonitis and intestinal abscess, graft-vs-host disease, chronic ulcer of the skin, deficiency and other anemias, hypovolemia, later complications after
transplant of whole organ, complications of transplanted and reattached limbs, depression, methicillin-sensitive Staphylococcus aureus infection [before VRE
BSI or VSE BSI], methicillin-resistant S. aureus infection [before VRE BSI or VSE BSI], antibiotic-sensitive gram-negative rods infection [before VRE BSI
or VSE BSI], antibiotic-resistant gram-negative rods infection [before VRE BSI or VSE BSI], and BSI not due to Enterococcus, S. aureus, or gram-negative
rods [before VRE BSI or VSE BSI]), and procedures (hemodialysis, mechanical ventilation for 196 hours during hospitalization, mechanical ventilation for
!96 hours during hospitalization, gastrostomy [temporary and permanent], bone marrow transplant, cancer chemotherapy, and insertion of central venous
catheter [during the 6-month period before enterococcal BSI infection for case patients or during the 6-month period before hospital discharge for uninfected
control patients]).
b Data are the median values of the difference between case-control pairs, and corresponding 95% CIs are based on the binomial distribution.
score–weighted GLS model, which allows for analysis of the
full cohort with the advantages of propensity score adjust-
ment to reduce confounding.
The wide variability in published cost estimates about VRE
BSI is due in part to differences in study designs, case defi-
nitions, control groups, sample sizes, and adjustment for con-
founders. Stosor et al4 reported that patients with VRE BSI
incurred crude mean hospitalization costs $27,000 higher
than the crude mean costs of patients with VSE BSI. Song et
al1 estimated the excess difference in median costs between
patients with VRE BSI and patients without BSI to be $77,558.
Song and colleagues1 calculated median costs by using pairs
matched by age, year of hospital admission, days of hospi-
talization prior to the diagnosis of BSI, principal diagnosis
and primary procedure (according to ICD-9-CM codes), and
the all-patient refined diagnosis-related group complexity level;
however, a number of important cost drivers also associated
with infection were not included in the analysis. Additional
cost estimates from studies involving other VRE infections (ie,
colonization or infection at sites other than the bloodstream)
range from $8,936 to $38,669.9,10,17-19
In both the standard GLS model and the propensity score–
weighted GLS model, vancomycin resistance was a highly
significant independent predictor of hospital costs, indicating
that expenditures for BSI due to resistant enterococci were
significantly higher than expenditures for BSI due to sensitive
enterococci. The costs attributable to vancomycin resistance
were $1,713 in the standard GLS model and $1,546 in the
propensity score–weighted GLS model. Of 4 published studies
that used multivariate methods to estimate the costs of van-
comycin resistance,1,9,10,17 only 2 studies attempted to assess
the independent financial impact of the acquisition of a re-
sistance determinant.9,10 Pelz et al10 did not find a significant
difference between the median costs of 117 ICU patients with
VRE ($33,251) or VSE ($21,914) urinary, wound, abscess, or
bloodstream infections (including catheter colonization).
However, the null result is likely due to small sample size (12
cases of VRE infection and 22 cases of VSE infection). Kaye
et al9 reported that vancomycin resistance was a significant
predictor of increased costs among patients with enterococcal
wound infection, with an attributable cost of $8,936. Our
estimates were substantially lower than the estimate by Kaye
et al,9 which may be related to our exclusion of surgical pa-
tients from the study population because of a markedly higher
distribution of costs for patients with operating room costs
compared with other hospitalized patients. It is also possible
that the costs attributable to vancomycin resistance vary ac-
cording to infection site.
Our finding that vancomycin resistance was indepen-
dently associated with increased hospital costs has a few
possible explanations. In our cohort, room and board costs
made up the highest percentage of total crude costs, ac-
counting for approximately one-half of total crude costs
regardless of BSI infection status. The positive correlation
between the incremental increases in crude room and board
costs ($20,213 for VRE BSI vs $10,127 for VSE BSI vs $3,976
for no BSI) and crude length of stay (14.6 days for VRE
BSI vs 10.0 days for VSE BSI vs 4.0 days for no BSI) indicates
that length of stay was the major driver of increased costs.
Pharmacy costs were the second largest contributor to total
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crude costs, making up 18%, 15%, and 8% of the total costs
for case patients with VRE BSI, case patients with VSE BSI,
and uninfected control patients, respectively. Antibiotic re-
sistance frequently leads to a delay in the administration of
appropriate antimicrobial therapy, which may be associated
with adverse outcomes.1,2,8,20-24 In addition, appropriate an-
timicrobial agents for treatment of VRE BSI cost signifi-
cantly more per day than antimicrobials typically used to
treat VSE BSI.8
Recent increases in rates of antibiotic-resistant infections6
highlight the need to standardize the methods for cost studies
of nosocomial infections. The use of readily available ad-
ministrative data is advantageous because they are relatively
inexpensive to obtain and are available at all hospitals in the
United States, facilitating the analysis of large cohorts.25 Our
study of 21,154 hospital inpatients has excellent power and
provides results that are generalizable to university-affiliated
tertiary care hospitals in the United States. It is important to
note that our data were restricted to a single institution. We
created comorbidity and procedure variables from ICD-9-
CM code data by using the Healthcare Cost and Utilization
Project Clinical Classifications Software as a guide, a stan-
dardized process that can improve comparability of cost es-
timates across studies. Compared with medical record data,
comorbidities are underreported in administrative data.25
Nevertheless, studies comparing diagnoses and procedures
reported in administrative data with those reported in medical
records and self-reporting have revealed good levels of agree-
ment.26 Furthermore, comorbidity adjustment by means of
diagnoses identified from claims data does not differ mark-
edly from comorbidity adjustment by means of diagnoses
identified from medical records.26-28
The significantly higher hospital costs of VRE BSI that we
identified in this study suggest that effective control of van-
comycin-resistant pathogens would result in cost savings. Re-
cent empirical evidence-based guidelines for the prevention
of VRE transmission recommend the use of active surveil-
lance cultures to identify the reservoir of the pathogen and
the use of the Centers for Disease Control and Prevention’s
long-recommended contact precautions to decrease trans-
mission.7 Other prevention strategies include the education
of healthcare workers, hand hygiene, judicious antimicrobial
use policies, and enhanced environmental cleaning.7,29,30 Our
estimates of the cost of vancomycin resistance can also be
used to help assess the cost-effectiveness of interventions to
reduce transmission of resistant organisms in hospitals.
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